• This record comes from PubMed

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

. 2015 Aug ; 100 (8) : e311-4. [epub] 20150313

Language English Country Italy Media print-electronic

Document type Letter, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/pmid25769539

Grant support
P01 CA081534 NCI NIH HHS - United States

E-resources Online Full text
Links

PubMed 25769539
PubMed Central PMC5004432
DOI 10.3324/haematol.2014.121459
PII: haematol.2014.121459
Knihovny.cz E-resources

See more in PubMed

Eketorp Sylvan S, Hansson L, Karlsson C, Norin S, Lundin J, Osterborg A. Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region. Leuk Lymphoma. 2014; 55(8):1774–1780. PubMed

Keating MJ, O’Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002; 43(9):1755–1762. PubMed

Tam CS, O’Brien S, Lerner S, et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma. 2007; 48(10):1931–1939. PubMed

Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006; 177(1):362–371. PubMed

Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010; 28(10):1749–1755. PubMed PMC

Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1(11):710–719. PubMed

Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008; 26(24):3913–3915. PubMed

Struemper H, Sale M, Patel BR, et al. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. J Clin Pharmacol. 2014; 54(7):818–827. PubMed

Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008; 111(12):5486–5495. PubMed

Coiffier B, Losic N, Ronn BB, et al. Pharmacokinetics and pharmaco-kinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1–2 study. Br J Haematol. 2010; 150(1):58–71. PubMed

Österborg A, Ronn BB, Jewell RC, et al. Correlation between serum ofatumumab concentrations, baseline patient characteristics and clinical outcomes in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL) treated with single-agent ofatumumab. Blood (ASH Annual Meeting, Abstract 3433). 2009;114(22).

van Oers MHJ, Kuliczkowski K, Smolej L, et al. Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results. Blood (ASH Annual Meeting Abstracts). 2014; 124(21).

Österborg A, Udvardy M, Zaritskey A, et al. Ofatumumab (OFA) vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242. Blood (ASH Annual Meeting, Abstract 4684). 2014;124(21).

Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3):213–223. PubMed PMC

Find record

Citation metrics

Archiving options